Clinical and immunological aspects of HIV infection in drug addicts

Massimo Galli(Luigi Sacco Hospital), Mauro Moroni(University of Milan), Claudia Balotta(University of Milan), Antonella Castagna(Vita-Salute San Raffaele University), Anna Lisa Ridolfo(University of Milan), Alberto Saracco(University of Milan), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Cristina Negri(University of Milan), Mario Corbellino(University of Milan), Adriano Lazzarin(Vita-Salute San Raffaele University)
Clinical Immunology and Immunopathology
January 1, 1989
10.1016/0090-1229(89)90124-4
Cited by 23

Related Papers

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
|Cell|2021|656
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362